James Black works four years as head of the department of pharmacology at University College in London where he establishes a new undergraduate course in medicinal chemistry.
James Black accepts a teaching position in a medical school in Singapore so that he can earn money to repay the debts incurred by his medical education.
James Black's research leads to the development of propranolol, a lifesaving breakthrough in the treatment of heart disease. Propranolol belongs to a class of drugs called beta-blocker and it is able to interrupt adrenaline's stimulating effect on the heart. It can also reduce the heart's need for oxygen. The medicine is used in treatment of angina, high blood pressure, migraine headaches, tremors, anxiety, and panic disorders.
James Black moves to the Wellcome Research Laboratories as Director of the therapeutic research division.
Under the influence of an older brother, who had also attended St. Andrews, James Black chooses to study medicine. A very important moment is for him the encounter with Professor D'Arcy Wentworth Thompson. After graduating with an MB ChB at University of St Andrews in Scotland, he joins the physiology department there as an Assistant Lecturer.
James Black joins Imperial Chemical Industries as a Senior Pharmacologist. He is very grateful to Dr Garnet Davey (subsequently Research Director) for his constant support during his six years of stay.
James Black is appointed Professor of analytical pharmacology at King’s College, London, becoming Emeritus in 1993. He serves as Chancellor of the University of Dundee in Scotland. In honour of his work, the university builds the Sir James Black Centre, a research facility for the investigation of cancer, tropical diseases, and diabetes.
James Black receives one third of the Nobel Prize in Physiology or Medicine along with Gertrude B. Elion and George H. Hitchings "for their discoveries of important principles for drug treatment". Black's invention of propranolol, the beta adrenergic receptor antagonist, has revolutionized the medical management of angina pectoris and it is considered to be one of the most important contributions to clinical medicine and pharmacology of the 20th century.
James Black is born in Uddingston, Lanarkshire, as fourth of five sons of a Baptist family.
James Black becomes head of biological research at Smith Kline & French Laboratories, where he works on new approaches to treating intestinal ulcers. Black develops his second major drug, cimetidine, which inhibits acid secretion in the stomach and is thus used to treat heartburn and ulcers. Cimetidine is launched under the brand name Tagamet in 1975.
James Black dies in London after a long illness at age 85.
James Black joins the Physiology Department under Professor R.C. Garry in October 1946 as an Assistant Lecturer.
Black equips a research laboratory with the newest cardiovascular technology at University of Glasgow Veterinary School. He begins research on the mechanism of increase in gastric secretions caused by the body's production of histamine. The foundation for his later work on blocking histamine receptors to reduce gastric secretions is laid. He works also with the alpha and betaadrenergic receptors, which are responsible for regulating heartbeat.
James Black becomes Chancellor at University of Dundee. He retires from his post the following year.
James Black is knighted by Queen Elizabeth II.
James Black attends Beath High School. He is a tireless daydreamer except during two periods of intense study— of music, between the ages of 12 and 14, and of mathematics, between the ages of 14 and 16. At the age of 15 he wins the Patrick Hamilton Residential Scholarship to study at University of St Andrews.